Form PTO 1449 US Department of Commerce Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

FORMATION DISCLOSURE January 30, 1997

ATTY DOCKET NO: SERIAL NO. 08/790,540

APPLICANT: William D. Huse

GROUP: January 30, 1997

U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)
			·			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

126	 Studnicka et al., "Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues," Protein Engineering , 7:805-814 (1994).

EXAMINER	GAMBEL	3/1/01	DATE CONSIDERED
		7 1	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.